1.27
前日終値:
$1.31
開ける:
$1.33
24時間の取引高:
11.56M
Relative Volume:
1.36
時価総額:
$348.10M
収益:
$188.87M
当期純損益:
$-400.38M
株価収益率:
-0.8467
EPS:
-1.5
ネットキャッシュフロー:
$-260.90M
1週間 パフォーマンス:
+5.83%
1か月 パフォーマンス:
+24.51%
6か月 パフォーマンス:
-35.53%
1年 パフォーマンス:
-19.11%
Pacific Biosciences Of California Inc Stock (PACB) Company Profile
名前
Pacific Biosciences Of California Inc
セクター
電話
650-521-8000
住所
1305 O'BRIEN DRIVE, MENLO PARK, CA
PACB を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
![]()
PACB
Pacific Biosciences Of California Inc
|
1.27 | 348.10M | 188.87M | -400.38M | -260.90M | -1.50 |
![]()
ABT
Abbott Laboratories
|
132.99 | 233.36B | 42.34B | 13.50B | 6.66B | 7.71 |
![]()
BSX
Boston Scientific Corp
|
101.30 | 147.06B | 17.55B | 2.03B | 2.72B | 1.37 |
![]()
SYK
Stryker Corp
|
375.56 | 145.64B | 23.22B | 2.86B | 3.58B | 7.40 |
![]()
MDT
Medtronic Plc
|
86.34 | 112.76B | 33.54B | 4.66B | 5.19B | 3.62 |
![]()
EW
Edwards Lifesciences Corp
|
73.83 | 44.46B | 5.54B | 4.18B | 623.10M | 7.00 |
Pacific Biosciences Of California Inc Stock (PACB) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2024-11-11 | ダウングレード | UBS | Buy → Neutral |
2024-06-03 | 再開されました | Jefferies | Buy |
2024-04-22 | ダウングレード | JP Morgan | Overweight → Neutral |
2024-04-18 | ダウングレード | Goldman | Buy → Neutral |
2023-12-14 | 開始されました | Guggenheim | Neutral |
2023-12-14 | 開始されました | Stephens | Overweight |
2023-12-13 | 開始されました | Wolfe Research | Peer Perform |
2023-11-17 | アップグレード | UBS | Neutral → Buy |
2023-10-31 | アップグレード | Cantor Fitzgerald | Neutral → Overweight |
2023-09-28 | 開始されました | Bernstein | Outperform |
2023-07-05 | 再開されました | JP Morgan | Overweight |
2023-06-30 | 開始されました | Goldman | Buy |
2023-05-10 | 開始されました | Barclays | Equal Weight |
2023-03-31 | アップグレード | TD Cowen | Market Perform → Outperform |
2023-02-02 | 開始されました | UBS | Neutral |
2023-01-20 | ダウングレード | Cantor Fitzgerald | Overweight → Neutral |
2023-01-05 | 開始されました | Scotiabank | Sector Outperform |
2022-01-21 | 再開されました | Cantor Fitzgerald | Overweight |
2022-01-06 | 再開されました | Piper Sandler | Neutral |
2021-10-15 | 再開されました | Cowen | Market Perform |
2021-09-27 | 開始されました | Canaccord Genuity | Buy |
2021-02-11 | アップグレード | Piper Sandler | Neutral → Overweight |
2020-11-03 | ダウングレード | Piper Sandler | Overweight → Neutral |
2020-10-02 | アップグレード | JP Morgan | Neutral → Overweight |
2020-09-09 | 開始されました | Morgan Stanley | Equal-Weight |
2020-06-02 | 再開されました | Cantor Fitzgerald | Overweight |
2020-03-09 | 再開されました | Cantor Fitzgerald | Overweight |
2019-10-15 | アップグレード | Piper Jaffray | Neutral → Overweight |
2019-04-02 | ダウングレード | Stephens | Overweight → Equal-Weight |
2018-10-19 | 開始されました | Cowen | Outperform |
2017-11-03 | ダウングレード | First Analysis Sec | Overweight → Equal-Weight |
2017-09-28 | ダウングレード | CL King | Buy → Neutral |
2016-11-03 | 繰り返されました | Cantor Fitzgerald | Buy |
2016-06-27 | 開始されました | CL King | Buy |
2016-04-15 | 開始されました | First Analysis Sec | Overweight |
2016-02-04 | ダウングレード | Piper Jaffray | Overweight → Neutral |
2016-01-04 | 繰り返されました | Cantor Fitzgerald | Buy |
2015-10-23 | アップグレード | Piper Jaffray | Neutral → Overweight |
2015-08-27 | 開始されました | Cantor Fitzgerald | Buy |
2015-02-04 | 繰り返されました | Maxim Group | Buy |
2013-09-26 | 繰り返されました | Maxim Group | Buy |
2013-01-14 | 繰り返されました | Maxim Group | Buy |
すべてを表示
Pacific Biosciences Of California Inc (PACB) 最新ニュース
Here's Why You Should Add PacBio Stock to Your Portfolio Now - MSN
Pacific Biosciences of California (PACB) Outperforms Broader Market: What You Need to Know - Yahoo Finance
Following a 41% decline over last year, recent gains may please Pacific Biosciences of California, Inc. (NASDAQ:PACB) institutional owners - simplywall.st
Celebrating Father’s Day with new discoveries of the Y chromosome achieved with HiFi sequencing - PacBio
Transcript : Pacific Biosciences of California, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-11-2025 10 - MarketScreener
PACB Q1 Earnings Call: Cost Reductions and Clinical Adoption Offset Market Headwinds - Yahoo Finance
Pacific Biosciences Approves Key Proposals at Annual Meeting - TipRanks
Powered by PacBio: Selected publications from May 2025 - PacBio
Pacific Biosciences Of California To Present At Jefferies Conference; Webcast At 8:45 AM ET - Nasdaq
Amgen To Present At Jefferies Healthcare Conference; Webcast At 9:20 AM ET - Nasdaq
Q1 Earnings Roundup: PacBio (NASDAQ:PACB) And The Rest Of The Life Sciences Tools & Services Segment - Yahoo Finance
Pacific Biosciences of California, Target ALS Collaborate for Genomic Study - marketscreener.com
PacBio (PACB) Joins Forces with Target ALS for Major Genomic Study | PACB Stock News - GuruFocus
Target ALS Chooses PacBio HiFi Sequencing to Advance ALS Research with Largest Global Genomic Study to Date - marketscreener.com
Pacific Biosciences of California: Sell Before Potential Reverse Split - Seeking Alpha
Shareholder Rights Advocates at Levi & Korsinsky Investigate Pacific Biosciences of California, Inc. (PACB) Regarding Possible Securities Fraud Violations - ACCESS Newswire
Media resourceS - PacBio
All You Need to Know About Pacific Biosciences (PACB) Rating Upgrade to Buy - sharewise
PureTarget repeat expansion and carrier panels enable high-throughput clinical research solutions - PacBio
PacBio to Present at Upcoming Investor Conferences - Yahoo Finance
Pacific Biosciences of California, Inc. (NASDAQ:PACB) Q1 2025 Earnings Call Transcript - MSN
PacBio Stock Slips Despite New China Distribution Deal With Haorui - sharewise
PACB stock touches 52-week low at $0.94 amid market challenges - Investing.com Australia
PacBio (PACB) Expands Presence in China with New Distribution De - GuruFocus
PacBio (PACB) Expands Presence in China with New Distribution Deal | PACB Stock News - GuruFocus
PacBio Expands Distribution in China, Gaining Access to New Clinical Lab Networks via Haorui Gene - Yahoo Finance
HiFi sequencing uncovers the secret to aging gracefully in Earth’s oldest living organisms - PacBio
Pacific Biosciences: A Mountain Of Red Flags (NASDAQ:PACB) - Seeking Alpha
Potential Upside For Pacific Biosciences of California, Inc. (NASDAQ:PACB) Not Without Risk - simplywall.st
PACB: Piper Sandler Adjusts Price Target for Pacific Biosciences - GuruFocus
PACB: Piper Sandler Adjusts Price Target for Pacific Biosciences | PACB Stock News - GuruFocus
PACB: Stephens & Co. Reiterates Overweight Rating | PACB Stock N - GuruFocus
Where Pacific Biosciences Stands With Analysts - Benzinga
PACB: Stephens & Co. Reiterates Overweight Rating | PACB Stock News - GuruFocus
PACB Price Target Reduced by Piper Sandler Following Quarterly R - GuruFocus
PACB Price Target Reduced by Piper Sandler Following Quarterly Results | PACB Stock News - GuruFocus
PacBio clears allegations after special investigation By Investing.com - Investing.com Nigeria
Metagenomics Market Size, Share, Forecast & Trends Analysis Report 2025: Market to Soar to $6.71 Billion by 2031, Driven by Agri Genomics and Genome Mapping - GlobeNewswire Inc.
PACB Stock May Rise Following the Deal With Chulalongkorn University - Nasdaq
PacBio (PACB) Completes Probe into Employment Practices and Cybe - GuruFocus
PacBio Board Independent Investigation Concludes Allegations Unsubstantiated - Yahoo Finance
Pacbio adjusts 2025 revenue guidance to $150M-$170M amid macroeconomic challenges - MSN
Pacific Biosciences of California First Quarter 2025 Earnings: EPS Misses Expectations - Yahoo Finance
PacBio (PACB) Sees Increased Options Activity Ahead of Earnings - GuruFocus
PacBio Stock Down Despite Q1 Earnings & Revenue Beat Estimates - Yahoo Finance
Pacific Biosciences Of California Inc (PACB) 財務データ
収益
当期純利益
現金流量
EPS
Pacific Biosciences Of California Inc (PACB) インサイダートレーディング
インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
---|---|---|---|---|---|---|---|
HENRY CHRISTIAN O | See Remarks |
Mar 03 '25 |
Sale |
1.41 |
12,497 |
17,583 |
2,225,357 |
Van Oene Mark | See Remarks |
Mar 03 '25 |
Sale |
1.41 |
6,486 |
9,126 |
1,497,695 |
Farmer Michele | See Remarks |
Mar 03 '25 |
Sale |
1.41 |
2,973 |
4,183 |
184,619 |
大文字化:
|
ボリューム (24 時間):